2014 - 2016 Spring Clinical Investigator Award
Application deadline: Monday, January 13, 2014
- To promote patient-oriented research conducted by surgical oncologists in clinical and translational science.
- Applicants must be surgical oncologists within 10 years of completion of training.
- Be full SSO members for at least 6 months prior to application submission to be eligible for the award.
Effective Spring 2014, it is no longer necessary for the applicant to commit at least 25% effort to the research project this award will support. Time committed should be reflected in the research proposal budget and will be taken into consideration as part of the overall assessment of the project. Terms of the Award
- The award will be funded for two years at $100,000 ($50,000 per year) beginning April 1, 2014. The Award concludes March 31, 2016.
- The award is given to the sponsoring institution and may be used for partial support of applicant’s salary, research fellows or staff support, tuition, travel (no more than $2,000 per year) and/or supplies. No additional funds are available for paying indirect costs.
- A brief year-one progress report with a financial update will be required by March 31, 2015. The JEF reserves the right to withhold the second year of support in the event of unsatisfactory progress.
- A final report (not to exceed 4 pages) will be required before February 15, 2016. This should include a summary of the project and abstracts and publications acknowledged as supported by this award as well as a financial reconciliation report.
- A brief (up to 10 minutes) presentation of results will be required at the March 2-5, 2016, SSO Annual Cancer Symposium in Boston, MA.
The James Ewing Foundation of the Society of Surgical Oncology requests a proposal in which the applicant plays a central role in the conduct of a specific clinical research project. This might include for example a leadership role in a clinical trial, in a prospective cancer outcomes study, or a translational research project related to a prospective clinical trial. The clinical research focus must be hypothesis-driven and must have a direct patient-oriented focus. Clinical trials may be investigator-initiated, industry-driven or organized by a cooperative group.While the applicant need not be the principal investigator of the trial, nor the lead institutional investigator, the extent to which the applicant is involved in study design and conduct must be clearly articulated. Ideal applicants will be early to mid-career investigators with a track record of peer-reviewed research funding who are seeking additional extramural support to further clinical cancer research. Of note, this award is not intended to serve as a career development award for new investigators seeking to initiate their research careers. The track record of the applicant, scientific merit of the application, novelty and clinical impact of the anticipated results, and resources available to ensure completion of the study will comprise the review criteria.
The application MUST include the following items in order:
A. Cover page: The cover page must include the following information: the title of the
proposal, name of applicant, applicant’s position, institution and contact information,
and the name and contact information for the individual authorized to act for the
applicant if the award is made.
B. Curriculum Vitae: A three-page bio sketch (including Other Support) in NIH format.
“Other Support” should list all grants and awards (one section for current and one section for those completed in the past three years). Each grant or award must include each of the following: 1) Title of the project/grant and name of funding source; 2) name of the PI and role of the applicant if not the PI; 3) percent effort; 4) dates of entire
project period; 5) award amount (direct dollars) for the current award period; 6) scientific overlap with proposed project; 7) manner in which any adjustments will be made for scientific overlap. Failure to include all information may be grounds to dismiss the application from scoring and consideration.
C. Supporting Letters: A letter from the applicant’s institution is required and should
include a review of the proposal and summary of the applicant’s qualifications. It should also describe the facilities and support available to complete the project. The letter should also specifically stipulate the percentage of time effort the applicant will devote to the research project. The letter should be from the institution’s cancer center director, chair of their department or dean of research. Other supporting letters (no more than 3) may be included.
D. Research Proposal:
This should include the following items:
- Abstract: The abstract should describe the clinical trial, the hypothesis being tested; specific aims of the research, and the novelty and clinical impact of the anticipated results. (Limited to 1 page, single spaced, 12 pt. font, one inch margin)
- Research plan: This section should focus on any critical preliminary data, overall and specific approaches/methodology, any alternative approaches, statistical plan if applicable, expected results, and the exact role of the applicant. (Limited to 6 pages, single spaced, 12 pt. font, one inch margin)
- Resources: This should include a brief description of the clinical cancer trials infrastructure at the applicant’s institution as well as any required resources in laboratory science, population science, epidemiology, bio specimen repositories, biostatistics, etc. (Limited to 1 page, single spaced, 12 pt. font, one inch margin)
- Literature cited. (no page limit)
Failure to adhere strictly to the page limits may be grounds to dismiss the application from scoring and consideration.
In no more than one (1) page, describe proposed budget utilization
and justification. Please identify the percentage of time that would be devoted to the research effort
and include any required indirect costs that would reduce the actual amount of direct research dollars available to the applicant. (The reviewers will take this information into account when reviewing applications and providing recommendations for funding.)
Clinical protocol, informed consent form, IRB approval notice. Summary
statements are acceptable.
- Not to exceed five (5) pages in length. If appendix exceeds the 5 page limit, the research proposal WILL NOT be reviewed.
The application deadline is Monday, January 13, 2014
The complete application must be assembled as a single .pdf file and sent
electronically to email@example.com by midnight January 13, 2014.
A hard copy of the application also must be submitted to the James Ewing Foundation c/o Society of Surgical Oncology, 9525 W. Bryn Mawr Ave., Suite 870, Rosemont, IL 60018, with a postmark of January 13.
Applications received after this date, or those that do not adhere strictly to the instructions, may not be considered. Award recipients will be announced at the 2014 SSO Annual Cancer
Symposium, and applicants will be informed of the outcome via email shortly after the
conclusion of the meeting. Please be aware that applicants will not receive reviewer comments or application score.
PLEASE NOTE: Funding of grants will be determined by scientific peer review process and
consistent with any restrictions required by the grantor.
Questions regarding the Clinical Investigator Awards? Contact Pamela Bowerman/JEF;
Email: firstname.lastname@example.org, or phone 847-427-1400, ext. 111, M-F, 8:30 a.m. - 4:30 p.m. (CT).
The SSO Foundation of the
Society of Surgical Oncology
9525 W. Bryn Mawr Ave., Suite 870
Rosemont, IL 60018
Phone : 847-427-1400, ext. 111